Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

The loss or absence of minimal residual disease of <0·1% at any time after two cycles of consolidation chemotherapy in CBFB–MYH11 ‐positive acute myeloid leukaemia indicates poor prognosis

Journal Article · · British Journal of Haematology
DOI:https://doi.org/10.1111/bjh.16745· OSTI ID:1635116
 [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1]
  1. Peking University People’s Hospital Peking University Institute of Hematology National Clinical Research Center for Hematology Disease Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation Beijing China
+ Show Author Affiliations

Summary

No consensus has been reached on the relationship between CBFB‐MYH11 copies and prognosis. Of 1525 acute myeloid leukemia (AML) patients, 58 with CBFB‐MYH11‐positive AML (16/58 patients with c‐kit mutation) were retrospectively analyzed with a median follow‐up duration of 29.8 (range: 4.8–74.4) months. Of these, 25/58 (43.1%) patients underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT), 10 of whom had the c‐kit mutation. Of the 33 patients who did not undergo allo‐HSCT, recurrence in patients with CBFB‐MYH11/ABL level >0.1% at any time after two consolidation cycles was significantly higher than in patients with CBFB‐MYH11/ABL level <0.1% (61.9% vs. 0%, P  = 0.001); further, the 3‐year relapse‐free survival (RFS; 31.4% vs. 100%, P  = 0.004) and event‐free survival (EFS; 33.1% vs. 100%, P  = 0.004) were significantly decreased in patients with CBFB‐MYH11/ABL level >0.1% at any time after two consolidation cycles. The 3‐year RFS and EFS rates were lower in patients who did not receive allo‐HSCT than in those who did (31.4% vs 84.6%, P  = 0.000; 31.4% vs. 80.8%, P  = 0.001). CBFB‐MYH11‐positive AML patients with CBFB‐MYH11/ABL level >0.1% at any time after two cycles of consolidation had poor prognoses, and allo‐HSCT could improve their survival.

Sponsoring Organization:
USDOE
OSTI ID:
1635116
Journal Information:
British Journal of Haematology, Journal Name: British Journal of Haematology Journal Issue: 2 Vol. 192; ISSN 0007-1048
Publisher:
Wiley-BlackwellCopyright Statement
Country of Publication:
United Kingdom
Language:
English

References (13)

Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience journal May 2010
Competing risk analysis using R: an easy guide for clinicians journal June 2007
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts journal June 2002
Is it time to change conventional consolidation chemotherapy for acute myeloid leukemia in CR1? journal January 2015
The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations journal October 2006
Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia journal August 1993
The Molecular Pathology of Acute Myeloid Leukemia journal January 2005
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG) journal January 2013
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party journal March 2018
Repetitive Cycles of High-Dose Cytarabine Benefit Patients With Acute Myeloid Leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461 journal March 2004
Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study journal August 2005
Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy journal May 2015
Core-Binding Factor Acute Myeloid Leukemia journal November 2011

Similar Records

Structure of the Leukemia-associated human CBFB gene
Journal Article · Mon Apr 10 00:00:00 EDT 1995 · Genomics · OSTI ID:209941
Effect of Smoking During Radiotherapy, Respiratory Insufficiency, and Hemoglobin Levels on Outcome in Patients Irradiated for Non-Small-Cell Lung Cancer
Journal Article · Tue Jul 15 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21124360
Impact of Consolidation Radiation Therapy in Stage III-IV Diffuse Large B-cell Lymphoma With Negative Post-Chemotherapy Radiologic Imaging
Journal Article · Thu Nov 01 00:00:00 EDT 2012 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:22149586

Related Subjects